WA
PCRX icon

Waverly Advisors’s Pacira BioSciences PCRX Stock Holding History

Waverly Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-800
Closed -$33K – 315
2015
Q3 		$33K Buy
800
+200
+33% +$12.3K 0.02% 189
2015
Q2 		$42K Buy
600
+400
+200% +$31.5K 0.03% 159
2015
Q1 		$18K Buy
+200
New +$20.3K 0.01% 203
2014
Q1 		– Sell
-197
Closed -$11K – 802
2013
Q4 		$11K Buy
+197
New +$10.4K ﹤0.01% 541

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Waverly Advisors's PCRX Position: Q4 2015 in Review

Waverly Advisors sold out of Pacira BioSciences (PCRX) in Q4 2015, closing a stake of 800 shares — an estimated $33K sold.

Waverly Advisors first reported a position in PCRX in Q4 2013 and held it in 4 quarters. The position peaked at $42K in Q2 2015. 214 funds tracked by Wall St. Rank hold PCRX as of Q4 2015.

  • Waverly Advisors reported no remaining Pacira BioSciences position as of Q4 2015 after selling out during the quarter.
  • Waverly Advisors sold 800 Pacira BioSciences shares in Q4 2015, an estimated $33K.
  • Waverly Advisors first reported a position in Pacira BioSciences in Q4 2013 and held it in 4 quarters.
  • Waverly Advisors's Pacira BioSciences position peaked at $42K in Q2 2015.
  • 214 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2015.

Based on Waverly Advisors's 13F filing for Q4 2015, filed 8 Feb 2016.